[{"id":"3327c6e3-f380-442f-b4aa-2aeb1a9c5fa0","acronym":"NivoPlus","url":"https://clinicaltrials.gov/study/NCT04107103","created_at":"2024-06-15T04:01:29.650Z","updated_at":"2024-07-02T16:34:25.737Z","phase":"Phase 2","brief_title":"Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04107103 - NivoPlus","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" TFRC","pipe":"","alterations":" ","tags":["TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 04/28/2023","study_completion_date":" 04/28/2023","last_update_posted":"2024-06-14"},{"id":"4d198146-63bc-4094-95ef-0d64c81f21ec","acronym":"DANTE","url":"https://clinicaltrials.gov/study/NCT03874858","created_at":"2021-01-18T19:06:17.053Z","updated_at":"2024-07-02T16:35:08.487Z","phase":"Phase 2","brief_title":"De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination","source_id_and_acronym":"NCT03874858 - DANTE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR • TFRC","pipe":"","alterations":" ","tags":["ABL1 • BCR • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/22/2019","start_date":" 03/22/2019","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-22"},{"id":"2bf15b4f-9a49-45d6-8256-e8bb3a627793","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598582","created_at":"2021-01-18T17:41:35.717Z","updated_at":"2024-07-02T16:37:08.648Z","phase":"Phase 4","brief_title":"Biological Predictive Factors of Response to ESA in Low Risk MDS Patients","source_id_and_acronym":"NCT03598582","lead_sponsor":"Association pour la recherche sur les Affections Malignes en Immunologie Sanguine","biomarkers":" CD34 • GDF15 • CD36 • TFRC","pipe":"","alterations":" ","tags":["CD34 • GDF15 • CD36 • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retacrit (epoetin alfa-epbx)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-07-26"}]